SNHG16 has also been implicated to be involved in resistance to sorafenib, a drug that is widely used for treating hepatocellular carcinoma (16–18), and has been described as a potential biomarker of unfavorable prognosis in a recent meta-analysis of 5 studies (19). This evidence concerns the gene SNHG16 and hepatocellular carcinoma.